ER, PR negative breast cancer, of which 50% is also Her2Neu receptor negative (triple negative), is biologically aggressive, resistant to conventional cytotoxic chemotherapy treatment, and is associated with reduced survival compared to other subtypes of breast cancer [20-23]. This evidence concerns the gene PGR and breast carcinoma.